(Hormone Receptor)
Indications and Usage, Adverse Reactions, Clinical Studies | | | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | MKI67 | Clinical Studies |
| | Dermatology | CYP2C19 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | KRAS | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Neurology | APOE | Warnings and Precautions, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Inborn Errors of Metabolism | GAA | Warnings and Precautions |
| | Oncology | HLA-B | Warnings |
| | Oncology | ERBB2 (HER2) | Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | PIK3CA | Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Neurology | NAT2 | Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology |
| | Neurology | NAT2 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| | Psychiatry | CYP2D6 | Precautions |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Rheumatology | NLRP3 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Drug Interactions, Clinical Studies |
| | Rheumatology | Gene Signature (IFN) | Clinical Pharmacology, Clinical Studies |
| | Pulmonary | UGT1A1 | Clinical Pharmacology |
| | Pulmonary | CYP2D6 | Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | PML-RARA | Indications and Usage, Clinical Studies |
| | Anesthesiology | G6PD | Warnings and Precautions |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Endocrinology | G6PD | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | Gene Signature (T-effector) | Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Gastroenterology | G6PD | Warnings and Precautions, Adverse Reactions |
| | Oncology | PDGFRA | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | KIT | Clinical Studies |
| | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| | Hematology | PROC | Warnings and Precautions |
| | Hematology | PROS1 | Warnings and Precautions |
| | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| | Hematology | CYP2C9 | Clinical Pharmacology |
| | Oncology | CD274 (PD-L1) | Clinical Studies |
| ) | Oncology | CBL | Clinical Studies |
| | Oncology | PTPN11 | Clinical Studies |
| | Oncology | RAS | Clinical Studies |
| | Rheumatology | TPMT | Dosage and Administration, Warnings, Precautions, Drug Interactions, Adverse Reactions, Clinical Pharmacology |
| | Rheumatology | NUDT15 | Dosage and Administration, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology |
| | Oncology | UGT1A1 | Dosage and Administration, Clinical Pharmacology |
| | Oncology | CYP2C19 | Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | UGT2B17 | Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | VHL | Clinical Studies |
| | Inborn Errors of Metabolism | CBS, MMADHC, MTHFR (Homocystinuria Deficiency) | Indications and Usage, Warnings and Precautions, Clinical Pharmacology, Clinical Studies |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | UGT1A1 | Clinical Pharmacology |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Adverse Reactions, Clinical Studies |
| | Oncology | CD19 | Indications and Usage |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | ALK | Use in Specific Populations, Clinical Studies |
| | Oncology | TNFRSF8 (CD30) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Neurology | CYP2C19 | Clinical Pharmacology |
| | Anesthesiology | G6PD | Warnings |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| | Infectious Diseases | HLA-B | Clinical Studies |
| | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| | Oncology | RET | Clinical Studies |
| | Oncology | MET | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | DPYD | Warnings and Precautions, Clinical Pharmacology, Patient Counseling Information |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | AKT1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | PIK3CA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | PTEN | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Neurology | HLA-B | Boxed Warning, Warnings, Precautions |
| | Neurology | HLA-A | Warnings |
| | Inborn Errors of Metabolism | NAGS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Rheumatology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology |
| | Cardiology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Infectious Diseases | G6PD | Warnings |
| | Infectious Diseases | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| | Rheumatology | CYP2C9 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | ALK | Indications and Usage, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Clinical Studies |
| | Oncology | ROS1 | Indications and Usage, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Dosage and Administration, Warning and Precautions, Adverse Reactions, Clinical Studies |
| | Inborn Errors of Metabolism | TPP1 | Indications and Usage, Use in Specific Populations, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Dental | CYP2D6 | Precautions |
| | Anesthesiology | G6PD | Warnings |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| | Endocrinology | G6PD | Precautions |
| | Inborn Errors of Metabolism | AMACR, AKR1D1, CYP7A1, CYP27A1, DHCR7, HSD3B2 (Bile Acid Synthesis Disorders) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | TPMT | Adverse Reactions |
| | Psychiatry | CYP2C19 | Dosage and Administration, Warnings, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Neurology | CYP2C19 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Precautions |
| | Cardiology | CYP2C19 | Boxed Warning, Warnings and Precautions, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Anesthesiology | CYP2D6 | Boxed Warning, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| | Hematology | HBB | Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | G6PD | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| | Oncology | RAS | Dosage and Administration, Warnings and Precautions |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Dermatology | G6PD | Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| | Dermatology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| | Infectious Diseases | G6PD | Precautions, Adverse Reactions, Overdosage |
| | Urology | CYP2D6 | Clinical Pharmacology |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | IL2RA (CD25 antigen) | Indications and Usage, Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings and Precautions, Clinical Pharmacology |
| | Hematology | F8 | Indications and Usage, Dosage and Administration, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Neurology | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| | Neurology | CYP2D6 | Warnings and Precautions, Clinical Pharmacology |
| | Neurology | CYP2C19 | Clinical Pharmacology |
| | Oncology | MYCN | Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| | Neurology | CYP2D6 | Clinical Pharmacology |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Psychiatry | CYP2C19 | Clinical Pharmacology |
| | Gastroenterology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| | Gynecology | CYP2C19 | Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Drug Interactions |
| | Oncology | ALK | Indications and Usage, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Clinical Pharmacology, Clinical Studies |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Neurology | ACHR | Indications and Usage, Clinical Studies |
| | Neurology | AQP4 | Indications and Usage, Clinical Studies |
| | Infectious Diseases | CYP2B6 | Clinical Pharmacology |
| | Neurology | ACHR | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| | Oncology | MYCN | Adverse Reactions, Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Gynecology | SLCO1B1 | Clinical Pharmacology |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Pulmonary | CFTR | Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Inborn Errors of Metabolism | CYP2D6 | Indications and Usage, Dosage and Administration, Contraindications, Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Oncology | Chromosome 4p;14q | Clinical Studies |
| | Oncology | Chromosome 14q;16q | Clinical Studies |
| | Inborn Errors of Metabolism | GALNS | Indications and Usage, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| | Hematology | Chromosome 7 | Adverse Reactions |
| | Hematology | Chromosome 13 | Adverse Reactions |
| | Hematology | PRF1, RAB27A, SH2D1A, STXBP2, STX11, UNC13D, XIAP (Hemophagocytic Lymphohistiocytosis) | Clinical Studies |
| | Oncology | IDH2 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| | Oncology | RAS | Dosage and Administration, Warnings and Precautions, Clinical Studies |
| | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | FGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies, Patient Counseling Information |
| | Oncology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| | Oncology | ERBB2 (HER2) | Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Infectious Diseases | G6PD | Precautions |
| | Psychiatry | CYP2D6 | Drug Interactions |
| | Psychiatry | CYP2C19 | Adverse Reactions |
| | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| | Gynecology | PROC | Contraindications |
| | Gynecology | PROS1 | Contraindications |
| | Gynecology | SERPINC1 (Antithrombin III) | Contraindications |
| | Gynecology | ESR, PGR (Hormone Receptor) | Warnings |
| | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Gastroenterology | CYP2C9 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Endocrinology | LDLR | Clinical Studies |
| | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indication and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Clinical Studies |
| | Urology | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| | Neurology | CYP2C9 | Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| | Neurology | HLA-B | Warnings and Precautions |
| | Gynecology | CYP2C9 | Clinical Pharmacology |
| | Gynecology | CYP2C19 | Adverse Reactions, Use in Specific Populations, Clinical Pharmacology |
| | Gynecology | CYP2D6 | Clinical Pharmacology |
| | Dermatology | DPYD | Contraindications, Warnings |
| | Oncology | DPYD | Warnings and Precautions, Patient Counseling Information |
| | Psychiatry | CYP2D6 | Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| | Rheumatology | CYP2C9 | Clinical Pharmacology |
| | Oncology | G6PD | Warnings |
| | Psychiatry | CYP2D6 | Drug Interactions |
| | Pulmonary | CYP2D6 | Clinical Pharmacology |
| | Pulmonary | CYP2C19 | Clinical Pharmacology |
| | Neurology | MOCS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | RAS | Indications and Usage, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | FGFR2 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Neurology | CYP2D6 | Clinical Pharmacology |
| | Neurology | CDKL5 | Indications and Usage, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | CYP2D6 | Clinical Pharmacology |
| | Onoclogy | CD33 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Infectious Diseases | MT-RNR1 | Warnings |
| | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Gastroenterology | CPOX, HMBS, PPOX (Acute Hepatic Porphyria) | Clinical Studies |
| | Endocrinology | G6PD | Warnings and Precautions, Adverse Reactions |
| | Endocrinology | G6PD | Precautions |
| | Endocrinology | G6PD | Precautions |
| | Inborn Errors of Metabolism | ASS1, CPS1, OTC (Urea Cycle Disorders) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Inborn Errors of Metabolism | NAGS | Indications and Usage |
| | Neurology | DMD | Indications and Usage, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| | Cardiology | Nonspecific (NAT) | Clinical Pharmacology |
| | Infectious Diseases | G6PD | Warnings and Precautions, Adverse Reactions |
| | Oncology | Chromosome 17p | Indications and Usage, Clinical Studies |
| | Oncology | Chromosome 11q | Clinical Studies |
| | Oncology | MYD88 | Clinical Studies |
| | Psychiatry | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| | Oncology | KIT | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | PDGFRB | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | FIP1L1-PDGFRA | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Endocrinology | Nonspecific (Heterozygous Familial Hypercholesterolemia) | Indications and Usage, Clinical Studies |
| | Pulmonary | UGT1A1 | Clinical Pharmacology |
| | Neurology | AQP4 | Indications and Usage, Clinical Studies |
| | Oncology | FGFR2 | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Neurology | TTR | Adverse Reactions, Clinical Pharmacology |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| | Oncology | HLA-A | Clinical Studies |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | UGT1A1 | Dosage and Administration, Warnings and Precautions, Clinical Pharmacology |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Oncology | Chromosome 4p;14q | Clinical Studies |
| | Oncology | Chromosome 14q;16q | Clinical Studies |
| | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings, Clinical Pharmacology |
| | Infectious Diseases | Nonspecific (NAT) | Clinical Pharmacology |
| | Cardiology | CYB5R | Overdosage |
| | Cardiology | CYB5R | Overdosage |
| | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Pulmonary | CFTR | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Neurology | CYP2C19 | Clinical Pharmacology |
| | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | HLA-DQA1 | Clinical Pharmacology |
| | Oncology | HLA-DRB1 | Clinical Pharmacology |
| | Oncology | NTRK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Neurology | APOE | Boxed Warning, Warnings and Precautions, Clinical Studies, Patient Counseling Information |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Hematology | Chromosome 5q | Boxed Warning, Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Pulmonary | PIK3CD | Clinical Studies |
| | Pulmonary | PIK3R1 | Clinical Studies |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Rheumatology | CYP2C9 | Drug Interactions, Clinical Pharmacology |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Endocrinology | Nonspecific (Congenital Hypothyroidism) | Indications and Usage, Warnings and Precautions, Use in Specific Populations |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| | Anesthesiology | G6PD | Warnings and Precautions, Clinical Pharmacology |
| | Anesthesiology | G6PD | Warnings and Precautions |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| | Anesthesiology | CYP2D6 | Use in Specific Populations |
| | Endocrinology | Nonspecific (Homozygous Familial Hypercholesterolemia) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Inborn Errors of Metabolism | LMNA | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Inborn Errors of Metabolism | ZMPSTE24 | Indications and Usage, Use in Specific Populations |
| | Oncology | ALK | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ROS1 | Adverse Reactions |
| | Urology | AGXT | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Hematology | HBB | Clinical Studies |
| | Hematology | F2 (Prothrombin) | Warnings and Precautions |
| | Hematology | F5 (Factor V Leiden) | Warnings and Precautions |
| | Hematology | PROC | Warnings and Precautions |
| | Hematology | PROS1 | Warnings and Precautions |
| | Hematology | SERPINC1 (Antithrombin III) | Warnings and Precautions |
| | Oncology | SSTR | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | FOLH1 (PSMA) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| | Gastroenterology | JAG1 | Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | FCGR2A (CD32A) | Clinical Pharmacology |
| | Oncology | FCGR2B (CD32B) | Clinical Pharmacology |
| | Oncology | FCGR3A (CD16A) | Clinical Pharmacology |
| | Cardiology | CYP2C19 | Dosage and Administration, Clinical Pharmacology |
| | Neurology | CYP2D6 | Warnings and Precautions |
| | Anesthesiology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology |
| | Anesthesiology | G6PD | Warnings |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| | Oncology | FIP1L1-PDGFRA | Adverse Reactions, Clinical Studies |
| | Oncology | TPMT | Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology |
| | Oncology | NUDT15 | Dosage and Administration, Warnings and Precautions, Clinical Pharmacology |
| | Hematology | G6PD | Contraindications, Warnings and Precautions |
| | Gastroenterology | CYB5R | Use in Specific Populations |
| | Gastroenterology | G6PD | Use in Specific Populations, Overdosage |
| | Gastroenterology | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Cardiology | CYP2D6 | Clinical Pharmacology |
| | Endocrinology | LEP | Contraindications |
| | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | NPM1 | Clinical Studies |
| | Oncology | KIT | Clinical Studies |
| | Inborn Errors of Metabolism | GLA | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| | Urology | CYP2D6 | Clinical Pharmacology |
| | Oncology | FOLR1 | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Hematology | PKLR | Clinical Studies |
| | Anesthesiology | BCHE | Warnings, Precautions, Clinical Pharmacology |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Transplantation | HPRT1 | Warnings and Precautions |
| | Infectious Diseases | G6PD | Precautions, Adverse Reactions |
| | Endocrinology | CYP2C9 | Drug Interactions |
| | Cardiology | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| | Nephrology | AGXT | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Infectious Diseases | MT-RNR1 | Warnings |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | UGT1A1 | Clinical Pharmacology |
| | Oncology | BRCA (Homologous Recombination Deficiency) | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Infectious Diseases | G6PD | Warnings, Adverse Reactions |
| | Oncology | APC | Clinical Studies |
| | Oncology | CTNNB1 | Clinical Studies |
| | Oncology | BRAF | Adverse Reactions, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Adverse Reactions, Clinical Studies |
| | Oncology | BRAF | Clinical Studies |
| | Oncology | CD274 (PD-L1) | Clinical Studies |
| | Oncology | LAG3 | Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Neurology | SMN2 | Clinical Pharmacology, Clinical Studies |
| | Oncology | MS4A1 (CD20 antigen) | Clinical Studies |
| | Gastroenterology | ABCB11 | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| | Gastroenterology | ATP8B1 | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| | Gastroenterology | JAG1 | Clinical Studies |
| | Gastroenterology | NOTCH2 | Clinical Studies |
| | Oncology | BRCA | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| | Oncology | BRCA, Genomic Instability (Homologous Recombination Deficiency) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | Homologous Recombination Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | PPP2R2A | Clinical Studies |
| | Oncology | PDGFRA | Clinical Studies |
| | Anesthesiology | CYP2D6 | Warnings and Precautions, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | IDH1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Clinical Studies |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| | Anesthesiology | G6PD | Warnings and Precautions |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings and Precautions |
| | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Gynecology | CYP2C9 | Clinical Pharmacology |
| | Gynecology | CYP2B6 | Clinical Pharmacology |
| | Neurology | HLA-B | Warnings and Precautions |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Gastroenterology | CYP2D6 | Clinical Pharmacology |
| | Oncology | EGFR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | RAS | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Gastroenterology | CYP2C19 | Clinical Pharmacology |
| | Inborn Errors of Metabolism | CASR | Indications and Usage, Clinical Studies |
| | Psychiatry | CYP2D6 | Drug Interactions, Clinical Pharmacology |
| | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | UGT1A1 | Clinical Pharmacology |
| | Oncology | HLA-B | Clinical Pharmacology |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology |
| | Rheumatology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions, Adverse Reactions, Patient Counseling Information |
| | Oncology | BRAF | Adverse Reactions, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | Tumor Mutational Burden | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Clinical Studies |
| | Oncology | FGFR1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | FGFR2 | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions, Clinical Pharmacology |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Neurology | CYP2C9 | Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| | Neurology | CYP2C19 | Clinical Pharmacology |
| | Neurology | HLA-B | Warnings and Precautions |
| | Psychiatry | CYP2D6 | Dosage and Administration, Precautions |
| | Rheumatology | CYP2C9 | Clinical Pharmacology |
| | Oncology | BTK | Clinical Studies |
| | Oncology | Chromosome 11q | Clinical Studies |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Oncology | IGHV | Clinical Studies |
| | Oncology | TP53 | Clinical Studies |
| | Psychiatry | CYP2D6 | Dosage and Administration, Use in Specific Populations, Clinical Pharmacology |
| | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| | Oncology | BCL2 | Clinical Studies |
| | Oncology | BCL6 | Clinical Studies |
| | Oncology | MYC | Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | CCDC6-RET, KIF5B-RET, RET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Cardiology | CYP2C19 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Cardiology | CYP2C9 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Cardiology | CYP3A5 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Cardiology | CYP2B6 | Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Infectious Diseases | G6PD | Contraindications, Warnings, Precautions, Adverse Reactions, Overdosage |
| | Infectious Diseases | CYB5R | Precautions, Adverse Reactions |
| | Rheumatology | G6PD | Adverse Reactions |
| | Cardiology | Nonspecific (NAT) | Adverse Reactions, Clinical Pharmacology |
| | Cardiology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| | Cardiology | CYP2D6 | Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Precautions |
| | Cardiology | CYP2D6 | Precautions |
| | Infectious Diseases | G6PD | Warnings and Precautions |
| | Infectious Diseases | CYP2D6 | Drug Interactions |
| | Oncology | FLT3 | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Gastroenterology | CYP2C19 | Drug Interactions, Clinical Pharmacology |
| | Oncology | ESR (Hormone Receptor) | Clinical Studies |
| | Infectious Diseases | UGT1A1 | Clinical Pharmacology |
| | Oncology | EGFR | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | RAS | Clinical Studies |
| | Oncology | G6PD | Boxed Warning, Contraindications, Warnings and Precautions |
| | Oncology | CYB5R | Boxed Warning, Contraindications, Warnings and Precautions |
| | Neurology | ACHR | Indications and Usage, Clinical Studies |
| | Oncology | RAS | Indications and Usage, Clinical Studies |
| | Oncology | ROS1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Neurology | CYP2C9 | Clinical Pharmacology |
| | Neurology | SMN1, SMN2 | Clinical Studies |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Oncology | MS4A1 (CD20 antigen) | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Cardiology | F5 (Factor V Leiden) | Clinical Studies |
| | Hematology | JAK2 | Clinical Pharmacology, Clinical Studies |
| | Anesthesiology | G6PD | Warnings |
| | Anesthesiology | Nonspecific (Congenital Methemoglobinemia) | Warnings |
| | Endocrinology | SLCO1B1 | Clinical Pharmacology |
| | Neurology | ACHR | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| | Neurology | MUSK | Indications and Usage, Clinical Pharmacology, Clinical Studies |
| | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | CYP2D6 | Clinical Pharmacology |
| | Oncology | CYP1A2 | Clinical Pharmacology |
| | Oncology | BRCA, Loss of Heterozygosity (Homologous Recombination Deficiency) | Warnings and Precautions, Adverse Reactions, Clinical Studies |
| | Oncology | UGT1A1 | Warnings and Precautions, Clinical Pharmacology |
| | Oncology | BRCA | Clinical Studies |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Inborn Errors of Metabolism | Nonspecific (Congenital Sucrase-Isomaltase Deficiency) | Indications and Usage, Adverse Reactions, Clinical Pharmacology |
| | Neurology | AQP4 | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | RET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Endocrinology | LEPR | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Endocrinology | PCSK1 | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Endocrinology | POMC | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Contraindications, Warnings, Clinical Pharmacology |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| | Neurology | CYP2C9 | Dosage and Administration, Contraindications, Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Toxicology | G6PD | Warnings and Precautions |
| | Toxicology | Nonspecific (Congenital Methemoglobinemia) | Boxed Warning, Warnings and Precautions |
| | Neurology | ALDH5A1 (Succinic Semialdehyde Dehydrogenase Deficiency) | Contraindications |
| | Inborn Errors of Metabolism | ASS1, CPS1, OTC (Urea Cycle Disorders) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Studies |
| | Oncology | KRAS | Indication and Usage, Dosage and Administration, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Infectious Diseases | MT-RNR1 | Warnings |
| | Hematology | G6PD | Clinical Pharmacology |
| | Anesthesiology | BCHE | Warnings, Precautions |
| | Anesthesiology | CACNA1S, RYR1 (Genetic Susceptibility to Malignant Hyperthermia) | Boxed Warning, Contraindications, Warnings, Precautions, Adverse Reactions, Clinical Pharmacology |
| | Infectious Diseases | G6PD | Warnings |
| | Infectious Diseases | G6PD | Precautions |
| | Infectious Diseases | Nonspecific (NAT) | Precautions |
| | Gastroenterology | G6PD | Precautions |
| | Gastroenterology | Nonspecific (NAT) | Clinical Pharmacology |
| | Gynecology | PROC | Contraindications |
| | Gynecology | PROS1 | Contraindications |
| | Gynecology | SERPINC1 (Antithrombin III) | Contraindications |
| | Cardiology | TTR | Clinical Pharmacology, Clinical Studies |
| | Infectious Diseases | G6PD | Dosage and Administration, Contraindications, Warnings and Precautions, Use in Specific Populations, Patient Counseling Information |
| | Oncology | BRCA | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | Homologous Recombination Repair | Indications and Usage, Dosage and Administrations, Adverse Reactions, Drug Interactions, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Indications and Usage, Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Oncology | F5 (Factor V Leiden) | Warnings and Precautions |
| | Oncology | F2 (Prothrombin) | Warnings and Precautions |
| | Oncology | CYP2D6 | Clinical Pharmacology |
| | Urology | CYP2D6 | Warnings and Precautions, Adverse Interactions, Clinical Pharmacology |
| | Oncology | HLA-A | Indications and Usage, Dosage and Administration, Clinical Studies |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Oncology | Chromosome 4p;14q | Clinical Studies |
| | Oncology | Chromosome 14q;16q | Clinical Studies |
| | Infectious Diseases | IFNL3 (IL28B) | Clinical Pharmacology, Clinical Studies |
| | Oncology | ALK | Clinical Studies |
| | Oncology | EGFR | Clinical Studies |
| | Oncology | MET | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Studies |
| | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| | Oncology | TPMT | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| | Oncology | NUDT15 | Dosage and Administration, Warnings, Precautions, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Contraindications, Warnings, Precautions |
| | Cardiology | CYP2C19 | Clinical Pharmacology |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Oncology | RAS | Indications and Usage, Clinical Studies |
| | Infectious Diseases | MT-RNR1 | Warnings and Precautions |
| | Oncology | SOD1 | Indications and Usage, Use in Specific Populations, Clinical Studies |
| | Endocrinology | G6PD | Precautions |
| | Endocrinology | G6PD | Precautions |
| | Urology | CYP2D6 | Warnings and Precautions, Drug Interactions, Clinical Pharmacology |
| | Oncology | ESR (Hormone Receptor) | Indications and Usage, Clinical Studies |
| | Anesthesiology | CYP2D6 | Boxed Warning, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology, Patient Counseling Information |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | G6PD | Adverse Reactions |
| | Oncology | RAS | Warnings and Precautions |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Clinical Pharmacology, Clinical Studies |
| | Oncology | ESR, PGR (Hormone Receptor) | Clinical Studies |
| | Oncology | PML-RARA | Indications and Usage, Dosage and Administration, Warnings and Precautions, Patient Counseling Information |
| | Inborn Errors of Metabolism | ACADVL, CPT2, HADHA, HADHB (Long-Chain Fatty Acid Oxidation Disorders) | Indications and Usage, Clinical Studies |
| | Oncology | ALK | Indications and Usage, Clinical Studies |
| | Oncology | EGFR | Indications and Usage, Clinical Studies |
| | Oncology | CD274 (PD-L1) | Clinical Studies |
| | Psychiatry | CYP2D6 | Precautions |
| | Neurology | MECP2 | Clinical Studies |
| | Oncology | ERBB2 (HER2) | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | Microsatellite Instability, Mismatch Repair | Indications and Usage, Dosage and Administration, Adverse Reactions, Clinical Studies |
| | Oncology | RAS | Clinical Studies |
| | Pulmonary | CYP2D6 | Clinical Pharmacology |
| | Rheumatology | CYP2D6 | Clinical Pharmacology |
| | Dermatology and Gastroenterology | IL12A, IL12B, IL23A | Warnings and Precautions |
| | Neurology | CYP2D6 | Dosage and Administration, Warnings and Precautions, Use in Specific Populations, Clinical Pharmacology |
| | Neurology | POLG | Boxed Warning, Contraindications, Warnings and Precautions |
| | Neurology | Nonspecific (Urea Cycle Disorders) | Contraindications, Warnings and Precautions |
| | Oncology | BRAF | Indications and Usage, Dosage and Administration, Warnings and Precautions, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies, Patient Counseling Information |
| | Oncology | RAS | Warnings and Precautions, Adverse Reactions |
| | Oncology | Chromosome 17p | Clinical Studies |
| | Oncology | Chromosome 11q | Clinical Studies |
| | Oncology | TP53 | Clinical Studies |
| | Oncology | IDH1 | Clinical Studies |
| | Oncology | IDH2 | Clinical Studies |
| | Oncology | IGHV | Clinical Studies |
| | Oncology | NPM1 | Clinical Studies |
| | Oncology | FLT3 | Clinical Studies |
| | Psychiatry | CYP2D6 | Drug Interactions, Use in Specific Populations, Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Clinical Pharmacology |
| | Psychiatry | SLCO1B1 | Clinical Pharmacology |
| | Neurology | DMD | Indications and Usage, Adverse Reactions, Use in Specific Populations, Clinical Pharmacology, Clinical Studies |
| | Oncology | BCR-ABL1 (Philadelphia chromosome) | Indications and Usage, Adverse Reactions, Clinical Studies |
| | Infectious Diseases | CYP2C19 | Clinical Pharmacology |
| | Psychiatry | CYP2D6 | Dosage and Administration, Clinical Pharmacology |
| | Hematology | HBB | Clinical Pharmacology, Clinical Studies |
| | Neurology | TTR | Adverse Reactions, Clinical Pharmacology, Clinical Studies |
| | Hematology | CYP2C9 | Dosage and Administration, Drug Interactions, Clinical Pharmacology |
| | Hematology | VKORC1 | Dosage and Administration, Clinical Pharmacology |
| | Hematology | PROS1 | Warnings and Precautions |
| | Hematology | PROC | Warnings and Precautions |
| | Oncology | MYD88 | Adverse Reactions, Clinical Studies |
| | Oncology | Chromosome 17p | Adverse Reactions, Clinical Studies |
| | Oncology | TP53 | Clinical Studies |
| | Neurology | ACHR | Indications and Usage, Clinical Studies |
Microplastics Are Everywhere. Here’s How to Avoid Eating Them.
![research paper on food labeling Katie Okamoto](https://cdn.thewirecutter.com/wp-content/media/2021/03/okamoto-katie.jpg?auto=webp&quality=60&crop=1:1&width=50)
By Katie Okamoto
Katie Okamoto is an editor focused on the environment. She has covered the intersection of products and sustainability for more than a decade.
Microplastics and nanoplastics are everywhere.
The teeny tiny pieces of plastic have been found in everything from drinking water to chicken nuggets, apples, and broccoli.
Recent studies have linked these pollutants to heart disease , lung disorders , and more worrying health issues.
But unfortunately, microplastics are now so pervasive that they’re nearly impossible to avoid.
If you’re concerned about the health effects linked to microplastics, the experts I spoke with said that you can lower your risk by taking care of your general health: getting plenty of sleep and exercise, eating a balanced diet, lowering stress, and seeking preventative care.
Still, it’s probably a good idea to lower your exposure to microplastics even if you can’t avoid them completely. Although you can cut back your exposure in as many ways as there are sources of plastic, the experts I spoke with recommended focusing on exposures from water, food, and air.
I talked to three doctors and a research scientist for tips on how to reduce the amount of tiny plastics and their chemicals that you (or your kids ) might ingest. Here’s what they recommend.
1. Cut back on bottled water
Bottled water is a significant source of microplastics. In fact, it’s the most concentrated source , according to a study from 2019.
Researchers believe that bottled water contains many more microplastics than tap. The evidence is mounting: A study published in 2024 suggests that the typical plastic bottle of water contains two to three times the plastic than previously thought.
Drinking bottled water in a pinch isn’t the end of the world, but for a daily habit, try carrying a reusable steel or glass bottle or tumbler when out and about.
2. Get an NSF-certified water filter
Switching to tap water from plastic bottled water will likely significantly reduce your routine exposure to plastics. But while the average plastic water bottle contains more microplastics and nanoplastics than tap, research shows that tap water may also be a source of microplastics.
Several of our water filter picks are specifically NSF/American National Standards Institute–certified to reduce microplastics, which means they’ve been rigorously tested in an accredited lab. They’re certified only to reduce since the filters cannot guarantee total elimination. Our picks include under-sink filters , such as the Aquasana AQ-5200 , and the Brita Elite , a pitcher filter .
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/31959/Aquasana-AQ-5200_20240528-173017_full.jpeg)
Aquasana AQ-5200
Exceptional, affordable under-sink filtration.
Certified for the most contaminants, widely available, affordable, and compact.
Buying Options
$100 + FS w/code AQWC50
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/21938/Brita-Elite-Filter_20240528-172838_full.jpeg)
Brita Elite Filter
Ace filtration, long lifespan.
This 10-cup, user-friendly model is rated to last six months between replacements.
Yes, it’s ironic that most NSF/ANSI-certified water filters contain plastic. But any microplastic shedding from using the plastic filter is likely to be minimal, as long as you avoid running hot water through the filter and store your water in the fridge, since heat accelerates plastic degradation.
Research suggests that boiling tap water, cooling it, and then filtering it may be especially effective at reducing microplastics, although it’s less practical for most people than simply using a filter.
3. Don’t use plastic to store food
Plastic food storage and packaging is so common that it’s difficult to avoid entirely. But your safest bet is to avoid storing food or liquid in plastic when possible and to minimize exposing any plastic (even those that say they’re BPA-free or microwave-safe) to high heat. Sunlight, acids, and physical erosion can also degrade plastic.
4. Don’t reuse single-use plastics for food and drinks
It’s great to reuse single-use plastic —just not for food. Unless you’re using the plastic in the freezer, save it for something that isn’t food storage or reheating, said Dr. Gillian Goddard, an endocrinologist and author at ParentData , a science-based online resource for parents. That means don’t reuse plastic takeout containers, breastmilk bags, or drink bottles.
5. Don’t microwave in plastic
Avoid microwaving or heating food or water in plastic—even if it says it’s microwave-safe, said Tracey Woodruff, director of the Program on Reproductive Health and the Environment at University of California San Francisco. Instead, consider glass or ceramic. The Pyrex Simply Store 18-Piece Set is our pick for the best food storage containers , and they survived our drop tests, stack neatly, and come with user-friendly lids (although you may not want to microwave the plastic lids). Our runner-up, the leakproof Glasslock 18-Piece Container Set , is another great option.
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/27033/Pyrex-18-Piece-Simply-Store-Food-Storage-Set_20180625-222257_full.jpeg)
Pyrex Simply Store 18-Piece Set
The best glass container set.
The Pyrex Simply Store containers stack neatly and are made from durable tempered glass. The colorful lids make it easier to match their shape to the corresponding container, though you may need to replace them over time.
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/14101/Glasslock-18-Piece-Container-Set_20240528-172635_full.jpeg)
Glasslock 18-Piece Container Set
The best leakproof glass container set.
The Glasslock containers have locking lids that will prevent leaks. But these lids also put stress on the lips of the containers, so the glass may be prone to chipping over time.
6. Wash plastic by hand
Dishwasher temperatures run very hot and can degrade plastic—even dishwasher-safe plastic—and lead to microplastic shedding. Try to wash your plastic food containers by hand.
7. Use wood or bamboo cutting boards
Some research suggests that plastic cutting boards can be a significant source of microplastics in your diet, since repeated cutting on their surface can dislodge particles that adhere to food. Wood cutting boards also have some other advantages: They’re better for your knife blades and last longer than plastic when properly maintained.
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/21192/Teakhaus-Medium-Professional-Carving-Board-with-Juice-Canal-109_20240528-172554_full.jpeg)
Teakhaus Medium Professional Carving Board with Juice Canal 109
The best wood cutting board.
This beautiful teak board requires more careful cleaning than a plastic board, but it feels better under a knife and is easier to maintain than the other wood boards we tested.
Our cutting board pick, the Teakhaus Medium Professional Carving Board with Juice Canal 109 , is made from sustainably harvested teak. If you still prefer plastic for certain uses, use it sparingly and replace it after heavy scarring.
8. Clean your air
The air we breathe is also a potential source of microplastics, in the form of dust. Reducing airborne dust in your home, then, may reduce your exposure to inhaled microplastics.
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/58162/SEBO-Airbelt-K3-Premium_20231113-094100_full.jpeg)
SEBO Airbelt K3 Premium
The best canister vacuum.
This bagged canister vacuum excels on both bare floors and carpets, and has many adjustment options and useful attachments. It should last for the long haul.
7-Year Standard Warranty
10-Year Extended Warranty
That means doing boring stuff, like vacuuming regularly with a bagged, sealed-system vacuum that has a HEPA or S-class filter and mopping and wiping down surfaces with a damp sponge or cloth (since dusting kicks those tiny particles back up into the air).
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/7595/Coway-AP-1512HH-Mighty_20181115-192655_full.jpeg)
Coway Airmega AP-1512HH Mighty
Exceptional, efficient, affordable.
Perfect for bedrooms, playrooms, and living rooms, this air purifier is one of the highest-performing, most-durable, and most-economical models we’ve tested.
You should also take care of seasonal chores like cleaning fans and AC unit filters and changing HVAC filters, and consider getting an air purifier if you live near a busy road.
Take special steps for infants and young children
Infants may be exposed to microplastics and nanoplastics in much higher concentrations than adults. Research shows that this exposure may be cause for concern, particularly at critical stages of early development. But much like health risks to adults, it’s important to think of microplastics exposure as just one piece of a child’s overall health.
“I emphasize that before putting much energy and resources into minimizing unknown risks, it is worth attending to reducing the risks we know about,” said Dr. Carlos Lerner, a pediatrician and professor of clinical pediatrics at UCLA Health. He cited following safe sleep recommendations for infants, avoiding secondhand smoke, and practicing good nutrition as examples.
If you want to take a more precautionary approach, avoid using plastic to warm formula or breastmilk. This is the main point of advice from the experts I spoke with, as well as the Cleveland Clinic .
1. Avoid microwaving or heating formula in plastic
Recent evidence shows that polypropylene-bottle-fed babies may swallow very high levels of tiny plastics due to the high temperatures used to sterilize bottles and prepare formula, as well as shaking the bottles to mix. If you want to feed your baby warmed formula and use plastic bottles, consider premixing the formula in a glass container, then cooling it down before transferring it to the feeding bottle.
2. Rinse heat-sterilized plastic bottles before adding formula or breastmilk
If you use heat to sterilize plastic bottles, leave them to cool then rinse them several times before filling them with formula or breastmilk, Lerner suggested.
3. Consider glass or silicone over plastic bottles
If you prefer to heat formula in a microwave, consider a glass or silicone bottle. The Philips Avent Glass Natural Response Baby Bottle is our recommendation for the best glass baby bottle.
![research paper on food labeling](https://d1b5h9psu9yexj.cloudfront.net/62239/Philips-Avent-Glass-Natural_20240528-172442_full.jpeg)
Philips Avent Glass Natural Response Baby Bottle
Our favorite glass bottles.
With only three pieces and a large, easy-to-screw-on collar, this glass bottle is simple to use and didn’t leak in our test. But the very wide nipple may not work well for all babies.
4. Wash hands before eating
For young kids who eat with their hands, try to establish a habit of handwashing before eating, said Woodruff. While handwashing is not always possible, it can help reduce exposure from touching microplastics in dust and soil (and maybe, just maybe, stem the tide of germs).
How worried should you be about microplastics?
Scientists are still studying the exact connections between these teeny tiny pieces of plastic and human health. But it’s clear that exposure to plastic—whether it’s those tiny particles, the chemicals they leach, or a combination—is being linked to a variety of worrying health issues.
Some of those connections still require more research, such as ties to colon cancer , respiratory disease , metabolic function , and disruption to endocrine systems , while others—like a recent study that found those with levels of plastics in their arteries were at a higher risk for heart attacks, strokes, and death—seem a little more clear.
It’s important to remember that these links point to concerns about the impact of microplastics on public health, but they are not specific, predictable outcomes. “What I’m thinking about is population risk, not a risk to a specific individual,” said Goddard.
The tricky thing is that microplastics and nanoplastics are impossible to avoid, no matter how diligent you are: They’re in the air we breathe , our drinking water , and our food. But scientists aren’t sure what levels of microplastics and nanoplastics we’re each taking in from those sources.
The oft-cited estimate that the average person eats a credit card’s worth of plastic every week has been called into question . But our bodies are certainly taking in plastic, and that’s more than nature intended.
Given the growing body of evidence, it’s possible that we’ll start to see more public health measures that address microplastic pollution. Until then, taking care of your overall health is the first line of defense, followed by taking reasonable steps to reduce microplastic exposure.
This article was edited by Christine Cyr Clisset and Ben Frumin.
Tracey Woodruff, director of the Program on Reproductive Health and the Environment at UCSF , phone interview , April 25, 2024
Gillian Goddard, MD, endocrinologist and adjunct assistant professor at NYU Langone Hospital and author of “Hot Flash” newsletter from ParentData , phone interview , April 26, 2024
Carlos Lerner, MD, pediatrician at the Children’s Health Center at UCLA and professor and Jack H. Skirball endowed chair in Pediatrics at UCLA , email interview , April 26, 2024
Hayley Goldbach, MD, board-certified physician and dermatologic surgeon at Brown University , email interview , April 29, 2024
Meet your guide
![research paper on food labeling](https://cdn.thewirecutter.com/wp-content/media/2021/03/okamoto-katie.jpg?auto=webp&quality=60&crop=1:1&width=150)
Katie Okamoto
Katie Okamoto is a writer and the editor of sustainability coverage at Wirecutter. She has been covering food and design products and their intersections with environment and health issues for more than a decade. Katie has also worked in design and sustainability, and she holds a bachelor’s in environmental studies, a master’s in architecture, and a professional certificate in life cycle assessment.
Mentioned above
- With eight different picks, we’ve found water bottles suited for everyone from gym rats to frequent travelers. The 8 Best Water Bottles
- The affordable, leak-resistant Simple Modern Classic Tumbler keeps drinks cold (or warm) for hours, and it comes with both a straw lid and a flip-top lid. The Best Tumbler
- After more than 30 hours researching hundreds of models, we’ve found the best under-sink water filtration systems for most people. Here’s what we recommend. The Best Under-Sink Water Filter
- Water filters and pitchers are the simplest, most affordable way to get reliable filtered water at home. The Best Water Filter Pitcher and Dispenser
- Most plastic isn’t actually recycled. These 12 tips can help you reduce your overall plastic use—and make a difference in the global plastic pollution problem. 12 Ways to Break Up With Single-Use Plastics
- After years of using and abusing food-storage containers, we recommend the glass Pyrex Simply Store 18-Piece Set and the Snapware Total Solution 20-Piece Set. The Best Food Storage Containers
Further reading
![research paper on food labeling Two bowls of fruit with silicone wraps on top, next to two glass containers of beans.](https://cdn.thewirecutter.com/wp-content/media/2023/10/siliconeisntsustainable-2048px-3x2-1.jpg?auto=webp&quality=60&crop=3:2&width=150)
Silicone Kitchen Gear Isn’t As Sustainable As Many People Think. Try These Solutions Instead.
by Katie Okamoto
We share how to get the most out of silicone items you may already own, and we recommend swaps you should consider instead of buying new tools and gadgets.
![research paper on food labeling reusablekitchen-2x1-4259](https://cdn.thewirecutter.com/wp-content/uploads/2019/12/reusablekitchen-lowres-4259.jpg?auto=webp&quality=60&crop=3:2&width=150)
The Best Reusable Produce Bags, Beeswax Wraps, and Other Ways to Reduce Plastic Waste
by Anna Perling
Our favorite alternatives to plastic or disposable food storage include silicone food-storage bags, beeswax wraps, and cloth produce bags.
![research paper on food labeling Several pieces of paper hanging from clothespins on a clothesline.](https://cdn.thewirecutter.com/wp-content/media/2024/04/laundry-detergent-sheets-2048px-0315-3x2-1.jpg?auto=webp&quality=60&crop=3:2&width=150)
Laundry Detergent Sheets Are Poor Cleaners. And Their Sustainability Claims Are Debatable.
by Andrea Barnes
Laundry detergent sheets claim to be a more-sustainable option than traditional liquid, powder, or pod detergents. Unfortunately, they don’t clean well.
![research paper on food labeling A person's hand pulling out a freezer bag of frozen corn from a freezer.](https://cdn.thewirecutter.com/wp-content/media/2023/06/freezingfood-2048px-1208513220-3x2-1.jpg?auto=webp&quality=60&crop=3:2&width=150)
Expert Tips for Freezing Food and Reducing Food Waste
by Anna Perling and Katie Okamoto
We have the best freezer containers, plus expert advice on saving money and reducing waste by getting the most from your freezer.
![research paper on food labeling FoodNavigator Europe](https://www.foodnavigator.com/content/download/1837/9283377?version=17)
- News & Analysis on Food & Beverage Development & Technology
![research paper on food labeling FoodNavigator Europe](https://www.foodnavigator.com/content/download/1837/10812?version=17)
Why do consumers trust – and distrust – meat alternatives?
07-Jun-2024 - Last updated on 07-Jun-2024 at 10:54 GMT
![research paper on food labeling Consumers trust alternative proteins more than ever, but there is still a long way to go. Image Source: Getty Images/jax10289](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_large/publications/food-beverage-nutrition/foodnavigator.com/news/market-trends/plant-based-meat-consumer-trust-and-distrust/17487991-1-eng-GB/Plant-based-meat-Consumer-trust-and-distrust.jpg)
Vegan and vegetarian meat alternatives are still a relatively new phenomenon in the West. Even the oldest companies producing them have been around for a significantly shorter period of time than animal agriculture, which stretches back 10,000 years. Thus, consumers still need time to get used to it.
Research from ‘consumer awareness’ organisation ProVeg International revealed that, while consumer trust in plant-based protein is increasing steadily, and they appear to be aware of the benefits, there is still a long way to go before trust levels are high enough for full adoption.
Why do some consumers not trust plant proteins?
Trust in plant proteins is higher than it once was, but there is still a long way to go. ProVeg’s research showed that while 46% of consumers assessed stated that their trust has improved or increased, 39% of consumers still do not trust them.
Trust, according to Elsa Guadarrama, consumer and market research manager at ProVeg International, regards consumers’ ‘knowledge and experience with plant-based alternatives.’ “Trust correlates quite well with increased consumption,” she suggested at the Smart Protein Closing Conference in Berlin last month.
Trust is often linked less to the actual safety of consuming plant proteins, Guadarrama suggested, but instead their supply chain.
Price parity and plant-based meat
Previous research by ProVeg has shown that one of the main barriers for consumer adoption of plant-based meat is cost. Price parity has on occasion been achieved, but in the overall market still remains a long way off.
One of the reasons for this, according to ProVeg CEO Jasmijn de Boo, is because the meat industry receives more subsidies than plant-based foods, giving it an advantage when it comes to costing.
“When looking at the statements related to trust, we see that the bottom two are 'integrity' and 'traceability', with 47% of agreement (still high). In contrast, safety to consume and accuracy in labelling are the top two drivers of 'trust' with 57% and 56% of agreement respectively,” she told FoodNavigator.
This can, she suggested, be remedied. “Traceability and credible certifications will (already are) playing an important role in fostering higher trust in plant-based alternatives.”
Why do consumers trust cultivated meat more than algae proteins?
ProVeg’s research also showed that cultivated meat is considered by consumers the second most trustworthy meat alternative category, following plant-based. This puts it above algae protein, a far more established category, with companies such as Quorn being on the market for decades. Cultivated meat, by contrast, has only very recently become commercially available, and then only in Singapore.
Trust in cultivated meat, suggested Guadarrama, may have something to do with the positive media coverage around it.
Cultivated meat commercialisation
While cultivated meat has been submitted for market approval in a range of places, including the EU and the UK , it has been approved in the US, Singapore and Israel. Of these, it is only Singapore where cultivated meat is commercially available.
There has even been some travel in the opposite direction. For example, Italy recently banned the production of cultivated meat.
“I think this is a good example of the power of the media. There has been so much media coverage around cultured meat and it's also been seen as this next step of meat, so there might be some influence of this positive futuristic approach to it,” she told FoodNavigator.
There has been other research, she told us, showing that those who are most likely to consume cultivated meat are actually males and omnivores.
Related news
![research paper on food labeling There are still barriers to full adoption of plant-based. Image Source: Getty Images/coldsnowstorm](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_medium/publications/food-beverage-nutrition/foodnavigator.com/news/policy/plant-based-meat-and-eu-policy/17473333-1-eng-GB/Plant-based-meat-and-EU-policy.jpg)
Related products
![research paper on food labeling Sustainable sourcing strategies for business continuity](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/news_teaser/publications/food-beverage-nutrition/foodnavigator.com/product-innovations/sustainable-sourcing-strategies-for-business-continuity/17447497-1-eng-GB/Sustainable-sourcing-strategies-for-business-continuity.jpg)
Sustainable sourcing strategies for business continuity
Content provided by Symrise | 21-May-2024 | White Paper
In 2022, heat waves and water shortages caused a 40% drop in tomato yields in key growing regions. This highlights the need for food and beverage manufacturers...
![research paper on food labeling TRANSITION FROM HOT FILL TO SUSTAINABLE ASEPTIC PACKAGING](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/news_teaser/publications/food-beverage-nutrition/foodnavigator.com/product-innovations/transition-from-hot-fill-to-sustainable-aseptic-packaging/17359323-1-eng-GB/TRANSITION-FROM-HOT-FILL-TO-SUSTAINABLE-ASEPTIC-PACKAGING.png)
TRANSITION FROM HOT FILL TO SUSTAINABLE ASEPTIC PACKAGING
Content provided by Husky Injection Molding Systems Ltd. | 10-May-2024 | Insight Guide
As the demand for sustainable aseptic beverage packaging continues to surge, brands and producers are seizing the opportunity to revolutionize their packaging...
![research paper on food labeling Case Study: Make Your Meat Go Further](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/news_teaser/publications/food-beverage-nutrition/foodnavigator.com/product-innovations/case-study-make-your-meat-go-further/17410872-1-eng-GB/Case-Study-Make-Your-Meat-Go-Further.jpg)
Case Study: Make Your Meat Go Further
Content provided by ADM | 07-May-2024 | Case Study
The rising cost of meat has become a significant concern for consumers worldwide, leading many to reconsider their dietary choices.
![research paper on food labeling Take Control with Predictive Modeling from Corbion](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/news_teaser/publications/food-beverage-nutrition/foodnavigator.com/product-innovations/take-control-with-predictive-modeling-from-corbion2/17382867-1-eng-GB/Take-Control-with-Predictive-Modeling-from-Corbion.jpg)
Take Control with Predictive Modeling from Corbion
Content provided by Corbion | 26-Apr-2024 | White Paper
Increased demand for uncured, higher pH formulations and natural products has made the challenge of controlling Listeria difficult. The good news: the...
Related suppliers
- Husky Injection Molding Systems Ltd.
- Rethink Events Ltd
- Sustainable sourcing strategies for business continuity Symrise | Download Technical / White Paper
- Your partner in plant-based meat alternatives ADM | Download Technical / White Paper
- TRANSITION FROM HOT FILL TO SUSTAINABLE ASEPTIC PACKAGING Husky Injection Molding Systems Ltd. | Download Insight Guide
- Enhance Your Product Line with Non-GMO Lecithin ADM | Download Product Brochure
- Case Study: Make Your Meat Go Further ADM | Download Case Study
- Take Control with Predictive Modeling from Corbion Corbion | Download Technical / White Paper
Upcoming editorial webinars
- 24 Sep 2024 Tue Webinar Decarbonising Supply Chains at the Source
- 25 Sep 2024 Wed Webinar Eco-friendly Production from Farm to Fork
- 26 Sep 2024 Thu Webinar New Tech and Novel Ingredients for a Sustainable Future
On-demand webinars
- Unlocking Consumer Emotions: A Comprehensive Framework for Emotional Associations in Food and Beverage Product Development
- Real-time Brix monitoring - the secret ingredient your process needs for quality and efficiency
- Sweet Solutions: Exploring the Future of Sugar Reduction
- Free-From Webinar
- Food for Kids Webinar
- Personalised Nutrition: Tapping into data for healthier diets Webinar
![research paper on food labeling Consumers trust alternative proteins more than ever, but there is still a long way to go. Image Source: Getty Images/jax10289](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_tiny/publications/food-beverage-nutrition/foodnavigator.com/news/market-trends/plant-based-meat-consumer-trust-and-distrust/17487991-1-eng-GB/Plant-based-meat-Consumer-trust-and-distrust.jpg)
Promotional features
![research paper on food labeling Start-ups with sustainable solutions for innovating food systems](https://www.foodnavigator.com/var/wrbm_gb_food_pharma/storage/images/_aliases/wrbm_tiny/publications/food-beverage-nutrition/foodnavigator.com/news/promotional-features/start-ups-with-sustainable-solutions-for-innovating-food-systems/17382057-1-eng-GB/Start-ups-with-sustainable-solutions-for-innovating-food-systems.jpg)
FoodNavigator
- Advertise with us
- Press Releases – Guidelines
- Apply to reuse our content
- Contact the Editor
- Report a technical problem
- Whitelist our newsletters
- Why Register
- Editorial Calendar
- Event Calendar
- Expert Advisory Panel
![research paper on food labeling research paper on food labeling](https://pubads.g.doubleclick.net/activity;dc_iu=/269346476/DFPAudiencePixel;ord=1;dc_seg=981818198?)
![](//myjudaica.online/777/templates/cheerup2/res/banner1.gif)
IMAGES
VIDEO
COMMENTS
The Special Issue "Food Labeling: Analysis, Understanding, and Perception" was conceived with the intention to further explore current efforts in food labeling research and welcomed original studies, as well as reviews of the literature, focusing on: (i) the analysis of the nutrient profile of products with different characteristics ...
The Special Issue " Food Labeling: Analysis, Understanding, and Perception " was conceived with the intention to further explore current efforts in food labeling research and welcomed original studies, as well as reviews of the literature, focusing on: (i) the analysis of the nutrient profile of products with different characteristics reported on the food labels, i.e., nutrition and health ...
The Special Issue " Food Labeling: Analysis, Understanding, and Perception" was con-. ceived with the intention to further explore current efforts in food labeling resear ch and. welcomed ...
Table 1 shows that 1017 review articles were obtained from the Scopus database, all focused on food and nutrition labelling (F & NL) research. Fig. 1 displays the publication trend of these 1017 articles over the years. The data depicted in Fig. 1 indicates a consistent and notable increase in the number of papers published on F&NL, and the year 2021 recorded the highest number of publications.
Sustainability labelling on food products can help consumers make informed purchasing decisions and support the urgent transition to sustainable food systems. While there is a relatively robust body of evidence on health and nutrition labelling, less is known about the effectiveness of sustainability labelling in facilitating sustainable food choices. This paper investigates the impact of ...
However, food labeling also represents a marketing tool and may influence perception of the food quality and, in turn, the dietary choice of consumers. For this reason, there is growing research in the food labeling field and in the evaluation of its effects on consumers, food operators, and the whole market [1,2].
The present paper reviews the literature on food labeling and its influence on consumer buying behavior to inform current investigations and identify areas of future research. A structured search ...
Feature papers represent the most advanced research with significant potential for high impact in the field. A Feature Paper should be a substantial original Article that involves several techniques or approaches, provides an outlook for future research directions and describes possible research applications. ... Food labelling should include ...
Research studies show that food label reading habit can help weight control, support healthy eating, and decrease the prevalence of chronic diseases (Güne et al, 2014), and health-conscious ...
An association between the use of nutrition labels and a healthy diet has been found in several studies. Those who use labels were found to be more likely to eat healthier foods, to have a reduced fat, 39 - 42 sodium, 43 cholesterol 44 and energy intake, and an increased fibre, iron 45 and vitamin C intake. 39.
Ecolabels are yet to be commonplace, but there are a number of reasons to think they may help shift consumer behavior. Nutrition and health labeling on foods is now widely implemented, with research showing such labels lead to small changes in purchasing and consumption behaviors, for example by reducing the energy content in food and drinks purchased and increasing purchasing of items with ...
Abstract. We examine a large-scale mandatory food labeling regulation to identify its effects on consumer behavior. We take advantage of exogenous variation in product-labeling status from the gradual and asynchronous introduction of labeled products on store shelves many weeks before the legal deadline. We combine individual-level scan data ...
The effectiveness of label use. The research on how labelling influences consumers can be divided into four measures of effectiveness: 1) self-reported use; 2) label comprehension as measured through self-reports or objective tests that gauge 'actual' understanding; 3) retail data to track how nutrition labels influence consumer purchasing ...
The focus groups were organized in three main phases: consumers' general perception of freshness and expiration dates (Day 1); consumers' practices in relation to purchase, use, storage, and disposal of red meat (Days 2-4): consumers' perception of smart labels and how these could affect consumers' food handling practices (Days 5-7). 2.2.1.
Background Obesity and chronic diseases could be prevented through improved diet. Most governments require at least one type of food labeling system on packaged foods to communicate nutrition information and promote healthy eating. This study evaluated adult consumer understanding and use of nutrition labeling systems in the US and Mexico, the most obese countries in the world. Methods Adults ...
Inclusion and exclusion criteria. To be considered, a published, in press or under review research paper had to meet the following criteria: (i) must relate to FOP nutrition labelling and/or shelf-labelling systems and consumer use, understanding, preference, perception or behaviour related to that label; (ii) the labels examined must include symbols or nutrition information flags located on ...
credence attributes. Across three essays, we provide an assessment of how different types of labels are used in the food system. We focus equally on labels that have a long and rich history in the food system (such as nutrition labels or geographical indication labeling, which denote a relationship between the product origin and specific product
This is not to say that man has not found need for labeling and regulation of food, for, in fact, food labeling has deep historical roots.3 Early Food Labeling Regulation: branding as a logistical aid to anti-adulteration enforcement A very interesting predecessor of food labeling existed in Roman time. In the Roman Empire, the rules
food labeling lawsuits, have resulted in consumer confusion and an uneven playing field in the marketplace. In light of these issues facing consumers and food producers, this paper offers
Original Paper; Published: 20 January 2024 (2024) ... Food labelling is a governance space in the sense that it is a forward attempt to influence the choices of ... The intersection of food law and legal metrology is a complex and important area of research. The effective regulation of food products requires accurate and reliable measurement ...
This research paper focuses on `The Impact of Food Labelling on Consumer's choice of Products - A Green Marketing Initiative'. It focuses on green marketing, how consumer perceives it and what are the real ingredients associated with it. This is the empirical research where the Likert scale is used to collect the primary data.
Research at the Bloomberg School is a team sport. In order to provide extensive guidance, infrastructure, and support in pursuit of its research mission, research@BSPH employs three core areas: strategy and development, implementation and impact, and integrity and oversight. Our exceptional research teams comprised of faculty, postdoctoral ...
Pharmacogenomics can play an important role in identifying responders and non-responders to medications, avoiding adverse events, and optimizing drug dose. Drug labeling may contain information on ...
Microplastics and nanoplastics are everywhere. The teeny tiny pieces of plastic have been found in everything from drinking water to chicken nuggets, apples, and broccoli. Recent studies have ...
A recent study by 'food awareness' non-profit ProVeg International revealed that meat eaters are more willing to try plant-based meat alternatives if they are clad in red packaging.. The study found that 56% of consumers in the UK, and 54% in the US, mentally connect the colour red with superior taste when it comes to plant-based meat.
Price parity and plant-based meat. Previous research by ProVeg has shown that one of the main barriers for consumer adoption of plant-based meat is cost. Price parity has on occasion been achieved, but in the overall market still remains a long way off. One of the reasons for this, according to ProVeg CEO Jasmijn de Boo, is because the meat ...
Cleveland Clinic researchers found higher amounts of the sugar alcohol xylitol are associated with increased risk of cardiovascular events like heart attack and stroke.. The team, led by Stanley Hazen, M.D., Ph.D., confirmed the association in a large-scale patient analysis, preclinical research models and a clinical intervention study.Findings were published today in the European Heart Journal.